济川药业：子公司获得复方聚乙二醇（3350）电解质散药品注册证书

Group 1 - The core point of the article is that Jichuan Pharmaceutical's subsidiary has received a drug registration certificate for Compound Polyethylene Glycol (3350) Electrolyte Powder, which is intended for the treatment of chronic constipation and fecal impaction [1] - The product is chocolate-flavored and is one of the five companies in China that have passed the consistency evaluation for this drug [1] - According to data from Minai Network, the sales revenue for Compound Polyethylene Glycol Electrolyte in urban public hospitals and retail pharmacies in China is projected to be 838 million yuan and 8 million yuan respectively in 2024 [1] Group 2 - The approval of the drug registration certificate is expected to have a positive impact on the company's future development [1] - However, the market development cycle for the drug's launch may take time and is subject to uncertainties influenced by pharmaceutical industry policies and procurement bidding [1]